Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.75 |
| ▸ | KDR | P35968 | 2/20 | 0.72 |
| ▸ | BRAF | P15056 | 2/20 | 0.72 |
| ▸ | CIT | O14578 | 1/20 | 0.72 |
| ▸ | GAK | O14976 | 1/20 | 0.72 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.72 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.72 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.72 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.72 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.72 |
| ▸ | STK17B | O94768 | 1/20 | 0.72 |
| ▸ | STK10 | O94804 | 1/20 | 0.72 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.72 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.72 |
| ▸ | ABL1 | P00519 | 1/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.72 |
| ▸ | LCK | P06239 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30879224 | 1.00 | EGFR (0.75) | EGFRKDRBRAFCITGAK | |
| SCHEMBL4220279 | 1.00 | EGFR (0.75) | EGFRKDRBRAFCITGAK | |
| SCHEMBL30119557 | 0.91 | EGFR (0.61) | EGFRKDRBRAFCITGAK | |
| SCHEMBL28538015 | 0.91 | EGFR (0.61) | EGFRKDRBRAFCITGAK | |
| SCHEMBL14971204 | 0.91 | EGFR (0.74) | EGFRKDRBRAFCITGAK | |
| SCHEMBL15078687 | 0.91 | EGFR (0.74) | EGFRKDRBRAFCITGAK | |
| SCHEMBL14971257 | 0.90 | EGFR (0.70) | EGFRKDRBRAFCITGAK | |
| SCHEMBL25341847 | 0.89 | EGFR (0.72) | EGFRKDRBRAFCITGAK | |
| SCHEMBL31502861 | 0.89 | EGFR (0.72) | EGFRKDRBRAFCITGAK | |
| SCHEMBL4226298 | 0.89 | EGFR (0.64) | EGFRKDRERBB2EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594275-B2 | Immunophilin binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| US-12558356-B2 | Immunophilin binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4612149-A1 | PYRIDO[2,3-D]PYRIMIDIN-2-AMINE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| EP-4612148-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2025-09-10 | — | — | EP | disclosed |
| US-20250108052-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-03 | — | — | US | disclosed |
| WO-2024094963-A1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-05-10 | — | — | WO | disclosed |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | PMP22, MAG, FABP7 | EGFR 3726/4885KDR 2930/4885BRAF 3868/4885 |
| US-12594275-B2 | Immunophilin binding agents and uses thereof | CCR1, CCRL2, CCR3 | EGFR 2717/4885KDR 1193/4885BRAF 3322/4885 |
| US-20250108052-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | SERPINA6, SELPLG, FABP7 | EGFR 3638/4885KDR 2741/4885BRAF 4452/4885 |
| US-12558356-B2 | Immunophilin binding agents and uses thereof | CCRL2, CFB, CCR3 | EGFR 1974/4885KDR 876/4885BRAF 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.